Back to News
Market Impact: 0.25
Psyence BioMed Plans $5 Mln Cash Investment In PsyLabs For U.S. Ibogaine Program
Source: Nasdaq
Healthcare & BiotechPrivate Markets & VentureCapital Returns (Dividends / Buybacks)
Psyence BioMed agreed to invest up to $5 million in cash in Psyence Labs and conduct a value-matched share exchange to support a planned U.S. Ibogaine program. The transaction provides funding and corporate alignment for the biotech program, but no clinical, regulatory, or financial-return milestones were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PBM0.55
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Australia says OpenAI agent hacked Medicare portal
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’
- A rare Microsoft bear warms up to the stock. Here's what changed their mind